Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
NCT01522183
This study is recruiting at 6 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Atypical Hemolytic-Uremic Syndrome
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- Any age
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Last updated on ClinicalTrials.gov
- September 16, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 1
- Clinical Trial Site · Aurora, CO
District of Columbia · 1
- Clinical Trial Site · Washington D.C., DC
Florida · 1
- Clinical Trial Site · Gainesville, FL
Georgia · 1
- Clinical Trial Site · Atlanta, GA
Massachusetts · 1
- Clinical Trial Site · Boston, MA
Missouri · 1
- Clinical Trial Site · St Louis, MO
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.